Penumbra (NYSE:PEN) was upgraded by investment analysts at TheStreet from a “d+” rating to a “c” rating in a research note issued to investors on Monday.

Other analysts have also recently issued reports about the company. ValuEngine raised Penumbra from a “hold” rating to a “buy” rating in a research report on Wednesday, September 12th. Canaccord Genuity reiterated a “buy” rating and set a $175.00 target price on shares of Penumbra in a research note on Monday, August 20th. Zacks Investment Research lowered Penumbra from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 26th. BMO Capital Markets increased their target price on Penumbra from $140.00 to $150.00 and gave the stock a “market perform” rating in a research note on Thursday, August 9th. Finally, Wells Fargo & Co reiterated an “outperform” rating and set a $180.00 target price (up previously from $150.00) on shares of Penumbra in a research note on Thursday, May 31st. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $158.60.

Shares of NYSE PEN opened at $152.15 on Monday. Penumbra has a 52 week low of $82.55 and a 52 week high of $167.35. The company has a market cap of $5.39 billion, a P/E ratio of -15,215.00, a P/E/G ratio of 29.58 and a beta of 0.10.

Penumbra (NYSE:PEN) last released its quarterly earnings data on Tuesday, August 7th. The company reported $0.15 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.03 by $0.12. Penumbra had a return on equity of 2.78% and a net margin of 7.19%. The company had revenue of $109.64 million during the quarter, compared to analysts’ expectations of $102.24 million. equities analysts predict that Penumbra will post 0.27 EPS for the current fiscal year.

In other Penumbra news, insider Daniel Donen Davis sold 7,500 shares of the firm’s stock in a transaction on Monday, August 20th. The stock was sold at an average price of $125.05, for a total transaction of $937,875.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Robert D. Evans sold 10,000 shares of the firm’s stock in a transaction on Monday, August 6th. The stock was sold at an average price of $150.16, for a total value of $1,501,600.00. Following the transaction, the executive vice president now owns 15,667 shares in the company, valued at approximately $2,352,556.72. The disclosure for this sale can be found here. In the last quarter, insiders have sold 71,407 shares of company stock worth $9,857,767. 10.70% of the stock is owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of PEN. Advisors Preferred LLC increased its stake in shares of Penumbra by 40.1% in the 2nd quarter. Advisors Preferred LLC now owns 1,220 shares of the company’s stock valued at $169,000 after purchasing an additional 349 shares during the last quarter. Prudential Financial Inc. increased its stake in shares of Penumbra by 14.1% in the 1st quarter. Prudential Financial Inc. now owns 3,237 shares of the company’s stock valued at $374,000 after purchasing an additional 400 shares during the last quarter. NumerixS Investment Technologies Inc increased its stake in shares of Penumbra by 20.0% in the 2nd quarter. NumerixS Investment Technologies Inc now owns 2,520 shares of the company’s stock valued at $354,000 after purchasing an additional 420 shares during the last quarter. Great West Life Assurance Co. Can increased its stake in shares of Penumbra by 17.8% in the 2nd quarter. Great West Life Assurance Co. Can now owns 3,230 shares of the company’s stock valued at $446,000 after purchasing an additional 489 shares during the last quarter. Finally, Xact Kapitalforvaltning AB increased its stake in shares of Penumbra by 15.2% in the 2nd quarter. Xact Kapitalforvaltning AB now owns 4,558 shares of the company’s stock valued at $630,000 after purchasing an additional 600 shares during the last quarter. Hedge funds and other institutional investors own 73.76% of the company’s stock.

About Penumbra

Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands.

Further Reading: Average Daily Trade Volume – What You Need to Know

Analyst Recommendations for Penumbra (NYSE:PEN)

Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.